These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 15765779)

  • 1. Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.
    Kojouri K; George JN
    Int J Hematol; 2005 Feb; 81(2):119-25. PubMed ID: 15765779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with refractory immune thrombocytopenic purpura.
    George JN
    J Thromb Haemost; 2006 Aug; 4(8):1664-72. PubMed ID: 16879206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura.
    George JN; Kojouri K; Perdue JJ; Vesely SK
    Semin Hematol; 2000 Jul; 37(3):290-8. PubMed ID: 10942223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of adult idiopathic thrombocytopenic purpura.
    Nakhoul IN; Kozuch P; Varma M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune thrombocytopenic purpura in adults.
    Godeau B; Provan D; Bussel J
    Curr Opin Hematol; 2007 Sep; 14(5):535-56. PubMed ID: 17934364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Refractory idiopathic thrombocytopenic purpura].
    Iki S; Urabe A
    Nihon Rinsho; 2003 Apr; 61(4):609-14. PubMed ID: 12718084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current options for the treatment of idiopathic thrombocytopenic purpura.
    Arnold DM; Kelton JG
    Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR; Segel E; Brandsborg M; d'Amore F
    Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
    Gómez-Almaguer D
    Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
    Latifzadeh SZ; Entezari V
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
    Panzer S
    Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune thrombocytopenic purpura in adults.
    Stasi R; Provan D
    Mayo Clin Proc; 2004 Apr; 79(4):504-22. PubMed ID: 15065616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the management of immune thrombocytopenic purpura in children.
    Tarantino MD; Bolton-Maggs PH
    Curr Opin Hematol; 2007 Sep; 14(5):526-34. PubMed ID: 17934363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
    Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
    Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.
    Vesely SK; Perdue JJ; Rizvi MA; Terrell DR; George JN
    Ann Intern Med; 2004 Jan; 140(2):112-20. PubMed ID: 14734334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
    Rodeghiero F
    Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.